Organization
Unidad de Gestión Clínica Intercentros de Oncología Médica
2 abstracts
Abstract
Ki67 as a prognostic factor in male breast cancer (male BC): Results from a large GEICAM Spanish cohort of male BC.Org: Gipuzkoa Cancer Unit- OSID/Onkologikoa-Osakidetza, GEICAM Spanish Breast Cancer Group, Hospital Universitario de Basurto, Hospital Clínico Universitario de Valencia, Institut Català d’Oncologia Hospitalet- Hospital Moises Broggi,
Abstract
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.Org: AstraZeneca, Winship Cancer Institute, Department of Thoracic Oncology, Kanagawa Cancer Center, Kanagawa Cancer Center, Cancer Center Clínica Universidad de Navarra, Madrid, Spain,